Amphastar Pharmaceuticals (AMPH) Expected to Post Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.8590 per share and revenue of $197.52 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The firm had revenue of $183.90 million during the quarter, compared to analysts’ expectations of $179.92 million. On average, analysts expect Amphastar Pharmaceuticals to post $2.43 EPS for the current fiscal year and $2.55 EPS for the next fiscal year.

Amphastar Pharmaceuticals Price Performance

NASDAQ AMPH opened at $27.03 on Tuesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.40. The firm’s 50 day moving average price is $24.87 and its 200-day moving average price is $22.30. Amphastar Pharmaceuticals has a 52-week low of $16.65 and a 52-week high of $29.52. The company has a market cap of $1.15 billion, a PE ratio of 15.99, a P/E/G ratio of 5.14 and a beta of 0.90.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Wall Street Zen lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Sunday. Weiss Ratings upgraded Amphastar Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 16th. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating for the company in a research report on Friday, August 7th. Barclays upped their price objective on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 18th. Finally, Wells Fargo & Company raised their price objective on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Seven equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Reduce” and an average target price of $22.50.

Insider Activity

In other news, Director Richard K. Prins sold 7,973 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $20.30, for a total transaction of $161,851.90. Following the transaction, the director owned 29,625 shares in the company, valued at $601,387.50. This represents a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO William J. Peters sold 4,139 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $25.00, for a total transaction of $103,475.00. Following the completion of the transaction, the chief financial officer directly owned 168,707 shares of the company’s stock, valued at $4,217,675. The trade was a 2.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 33,479 shares of company stock worth $763,922. Insiders own 29.60% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.